NO2887953T3 - - Google Patents

Info

Publication number
NO2887953T3
NO2887953T3 NO13838871A NO13838871A NO2887953T3 NO 2887953 T3 NO2887953 T3 NO 2887953T3 NO 13838871 A NO13838871 A NO 13838871A NO 13838871 A NO13838871 A NO 13838871A NO 2887953 T3 NO2887953 T3 NO 2887953T3
Authority
NO
Norway
Application number
NO13838871A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2887953T3 publication Critical patent/NO2887953T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO13838871A 2012-08-23 2013-08-22 NO2887953T3 (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2452MU2012 2012-08-23
PCT/IN2013/000511 WO2014045296A2 (en) 2012-08-23 2013-08-22 Improved daptomycin injectable formulation

Publications (1)

Publication Number Publication Date
NO2887953T3 true NO2887953T3 (enExample) 2018-03-10

Family

ID=54187094

Family Applications (1)

Application Number Title Priority Date Filing Date
NO13838871A NO2887953T3 (enExample) 2012-08-23 2013-08-22

Country Status (12)

Country Link
US (1) US20150216928A1 (enExample)
EP (2) EP3287138A1 (enExample)
JP (1) JP2015526463A (enExample)
AU (2) AU2013319737B2 (enExample)
BR (1) BR112015003198A2 (enExample)
CA (1) CA2881121A1 (enExample)
DK (1) DK2887953T3 (enExample)
ES (1) ES2655215T3 (enExample)
NO (1) NO2887953T3 (enExample)
PT (1) PT2887953T (enExample)
SI (1) SI2887953T1 (enExample)
WO (1) WO2014045296A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4066849T3 (pl) * 2012-09-11 2025-06-16 Hospira Australia Pty Ltd Preparaty daptomycyny i ich zastosowania
WO2018073269A1 (en) 2016-10-21 2018-04-26 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
US11759497B2 (en) 2017-08-31 2023-09-19 Xellia Pharmaceuticals Aps Daptomycin formulations
EP4110303A1 (en) 2020-02-28 2023-01-04 Xellia Pharmaceuticals ApS Daptomycin formulation
EP4117625A1 (en) 2020-03-12 2023-01-18 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
CN112684043A (zh) * 2020-12-16 2021-04-20 南京健友生化制药股份有限公司 一种达托霉素有关物质的检测方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
FR2657526B1 (fr) * 1990-01-31 1994-10-28 Lvmh Rech Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues.
CN1069320C (zh) * 1995-10-17 2001-08-08 昭和电工株式会社 高纯度生育酚磷酸酯,其生产方法和含有该化合物的化妆品
JP4088597B2 (ja) * 2004-01-06 2008-05-21 樹男 飯田 内服および注射用組成物とその製法
CA2564180A1 (en) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical preparation containing bacterial cell wall skeleton component
US9168216B2 (en) * 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
CN102625697A (zh) * 2009-09-01 2012-08-01 西北大学 使用经寡核苷酸修饰的纳米颗粒作为载体来递送治疗剂
US8431539B2 (en) * 2009-09-17 2013-04-30 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
CA2781666C (en) * 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
WO2011094814A1 (en) * 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CA2752784A1 (en) * 2010-09-21 2012-03-21 Xellia Pharmaceuticals Aps Daptomycin formulation

Also Published As

Publication number Publication date
PT2887953T (pt) 2018-01-10
AU2013319737A1 (en) 2015-02-05
EP2887953A4 (en) 2016-05-25
EP2887953B1 (en) 2017-10-11
EP3287138A1 (en) 2018-02-28
ES2655215T3 (es) 2018-02-19
JP2015526463A (ja) 2015-09-10
WO2014045296A2 (en) 2014-03-27
DK2887953T3 (en) 2018-01-15
US20150216928A1 (en) 2015-08-06
CA2881121A1 (en) 2014-03-27
WO2014045296A3 (en) 2014-10-23
EP2887953A2 (en) 2015-07-01
AU2018204334A1 (en) 2018-07-05
BR112015003198A2 (pt) 2017-10-10
SI2887953T1 (en) 2018-02-28
AU2013319737B2 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
BR112014017635A2 (enExample)
BR112014017614A2 (enExample)
BR112014018331A2 (enExample)
BR112014017625A2 (enExample)
BR112014017659A2 (enExample)
BR112014017607A2 (enExample)
BR112014017592A2 (enExample)
BR112014017646A2 (enExample)
BR112014017638A2 (enExample)
AR092201A1 (enExample)
BR112013027865A2 (enExample)
BR112014026869B8 (enExample)
BR112014017609A2 (enExample)
BR112014017644A2 (enExample)
BR112014019843A2 (enExample)
BR112014017634A2 (enExample)
BR112014017588A2 (enExample)
BR112014017647A2 (enExample)
BR112014013184A8 (enExample)
BR112014017627A2 (enExample)
BR112014017630A2 (enExample)
BR112014017641A2 (enExample)
BR112014017621A2 (enExample)
BR112014017631A2 (enExample)
BR112014020219A2 (enExample)